BACKGROUND:Morbidity from asthma is disproportionately higher among black patients than among white patients, and black patients constitute the minority of participants in trials informing treatment. Data indicate that patients with inadequately controlled asthma benefit more from addition of a long-acting beta-agonist (LABA) than from increased glucocorticoids; however, these data may not be informative for treatment in black patients. METHODS: We conducted two prospective, randomized, double-blind trials: one involving children and the other involving adolescents and adults. In both trials, the patients had at least one grandparent who identified as black and had asthma that was inadequately controlled with low-dose inhaledglucocorticoids. We compared combinations of therapy, which included the addition of a LABA (salmeterol) to an inhaled glucocorticoid (fluticasone propionate), a step-up to double to quintuple the dose of fluticasone, or both. The treatments were compared with the use of a composite measure that evaluated asthma exacerbations, asthma-control days, and lung function; data were stratified according to genotypic African ancestry. RESULTS: When quintupling the dose of fluticasone (to 250 μg twice a day) was compared with adding salmeterol (50 μg twice a day) and doubling the fluticasone (to 100 μg twice a day), a superior response occurred in 46% of the children with quintupling the fluticasone and in 46% of the children with doubling the fluticasone and adding salmeterol (P = 0.99). In contrast, more adolescents and adults had a superior response to added salmeterol than to an increase in fluticasone (salmeterol-low-dose fluticasone vs. medium-dose fluticasone, 49% vs. 28% [P = 0.003]; salmeterol-medium-dose fluticasone vs. high-dose fluticasone, 49% vs. 31% [P = 0.02]). Neither the degree of African ancestry nor baseline biomarkers predicted a superior response to specific treatments. The increased dose of inhaled glucocorticoids was associated with a decrease in the ratio of urinary cortisol to creatinine in children younger than 8 years of age. CONCLUSIONS: In contrast to black adolescents and adults, almost half the black children with poorly controlled asthma had a superior response to an increase in the dose of an inhaled glucocorticoid and almost half had a superior response to the addition of a LABA. (Funded by the National Heart, Lung, and Blood Institute; BARD ClinicalTrials.gov number, NCT01967173.).
RCT Entities:
BACKGROUND: Morbidity from asthma is disproportionately higher among black patients than among white patients, and black patients constitute the minority of participants in trials informing treatment. Data indicate that patients with inadequately controlled asthma benefit more from addition of a long-acting beta-agonist (LABA) than from increased glucocorticoids; however, these data may not be informative for treatment in black patients. METHODS: We conducted two prospective, randomized, double-blind trials: one involving children and the other involving adolescents and adults. In both trials, the patients had at least one grandparent who identified as black and had asthma that was inadequately controlled with low-dose inhaled glucocorticoids. We compared combinations of therapy, which included the addition of a LABA (salmeterol) to an inhaled glucocorticoid (fluticasone propionate), a step-up to double to quintuple the dose of fluticasone, or both. The treatments were compared with the use of a composite measure that evaluated asthma exacerbations, asthma-control days, and lung function; data were stratified according to genotypic African ancestry. RESULTS: When quintupling the dose of fluticasone (to 250 μg twice a day) was compared with adding salmeterol (50 μg twice a day) and doubling the fluticasone (to 100 μg twice a day), a superior response occurred in 46% of the children with quintupling the fluticasone and in 46% of the children with doubling the fluticasone and adding salmeterol (P = 0.99). In contrast, more adolescents and adults had a superior response to added salmeterol than to an increase in fluticasone (salmeterol-low-dose fluticasone vs. medium-dose fluticasone, 49% vs. 28% [P = 0.003]; salmeterol-medium-dose fluticasone vs. high-dose fluticasone, 49% vs. 31% [P = 0.02]). Neither the degree of African ancestry nor baseline biomarkers predicted a superior response to specific treatments. The increased dose of inhaled glucocorticoids was associated with a decrease in the ratio of urinary cortisol to creatinine in children younger than 8 years of age. CONCLUSIONS: In contrast to black adolescents and adults, almost half the black children with poorly controlled asthma had a superior response to an increase in the dose of an inhaled glucocorticoid and almost half had a superior response to the addition of a LABA. (Funded by the National Heart, Lung, and Blood Institute; BARD ClinicalTrials.gov number, NCT01967173.).
Authors: Rajesh Kumar; Max A Seibold; Melinda C Aldrich; L Keoki Williams; Alex P Reiner; Laura Colangelo; Joshua Galanter; Christopher Gignoux; Donglei Hu; Saunak Sen; Shweta Choudhry; Edward L Peterson; Jose Rodriguez-Santana; William Rodriguez-Cintron; Michael A Nalls; Tennille S Leak; Ellen O'Meara; Bernd Meibohm; Stephen B Kritchevsky; Rongling Li; Tamara B Harris; Deborah A Nickerson; Myriam Fornage; Paul Enright; Elad Ziv; Lewis J Smith; Kiang Liu; Esteban González Burchard Journal: N Engl J Med Date: 2010-07-07 Impact factor: 91.245
Authors: Katherine A Drake; Dara G Torgerson; Christopher R Gignoux; Joshua M Galanter; Lindsey A Roth; Scott Huntsman; Celeste Eng; Sam S Oh; Sook Wah Yee; Lawrence Lin; Carlos D Bustamante; Andrés Moreno-Estrada; Karla Sandoval; Adam Davis; Luisa N Borrell; Harold J Farber; Rajesh Kumar; Pedro C Avila; Emerita Brigino-Buenaventura; Rocio Chapela; Jean G Ford; Michael A Lenoir; Fred Lurmann; Kelley Meade; Denise Serebrisky; Shannon Thyne; William Rodríguez-Cintrón; Saunak Sen; José R Rodríguez-Santana; Ryan D Hernandez; Kathleen M Giacomini; Esteban G Burchard Journal: J Allergy Clin Immunol Date: 2013-08-29 Impact factor: 10.793
Authors: Stephen P Peters; Susan J Kunselman; Nikolina Icitovic; Wendy C Moore; Rodolfo Pascual; Bill T Ameredes; Homer A Boushey; William J Calhoun; Mario Castro; Reuben M Cherniack; Timothy Craig; Loren Denlinger; Linda L Engle; Emily A DiMango; John V Fahy; Elliot Israel; Nizar Jarjour; Shamsah D Kazani; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Njira Lugogo; Richard J Martin; Deborah A Meyers; Joe Ramsdell; Christine A Sorkness; E Rand Sutherland; Stanley J Szefler; Stephen I Wasserman; Michael J Walter; Michael E Wechsler; Vernon M Chinchilli; Eugene R Bleecker Journal: N Engl J Med Date: 2010-09-19 Impact factor: 91.245
Authors: Sharmilee M Nyenhuis; Jerry A Krishnan; Alalia Berry; William J Calhoun; Vernon M Chinchilli; Linda Engle; Nicole Grossman; Fernando Holguin; Elliot Israel; Rick A Kittles; Monica Kraft; Stephen C Lazarus; Erik B Lehman; David T Mauger; James N Moy; Stephen P Peters; Wanda Phipatanakul; Lewis J Smith; Kaharu Sumino; Stanley J Szefler; Michael E Wechsler; Sally Wenzel; Steven R White; Steven J Ackerman Journal: J Allergy Clin Immunol Date: 2017-01-06 Impact factor: 10.793
Authors: Amr El-Ekiaby; Lori Brianas; Mary E Skowronski; Albert J Coreno; Gayle Galan; Frank J Kaeberlein; Roy E Seitz; Karen D Villaba; Howard Dickey-White; E R McFadden Journal: Am J Respir Crit Care Med Date: 2006-06-08 Impact factor: 21.405
Authors: Corinne A Keet; Meredith C McCormack; Craig E Pollack; Roger D Peng; Emily McGowan; Elizabeth C Matsui Journal: J Allergy Clin Immunol Date: 2015-01-20 Impact factor: 10.793
Authors: Jennifer A Rumpel; Brian K Ahmedani; Edward L Peterson; Karen E Wells; Mao Yang; Albert M Levin; James J Yang; Rajesh Kumar; Esteban González Burchard; L Keoki Williams Journal: J Allergy Clin Immunol Date: 2012-10-12 Impact factor: 10.793
Authors: Louis-Philippe Boulet; Hélène Turcotte; Philippe Prince; Catherine Lemière; Ronald Olivenstein; Catherine Laprise; Pierre Larivée; Paul Bégin; Michel Laviolette Journal: Respir Med Date: 2009-08-18 Impact factor: 3.415
Authors: Victor E Ortega; Michelle Daya; Stanley J Szefler; Eugene R Bleecker; Vernon M Chinchilli; Wanda Phipatanakul; Dave Mauger; Fernando D Martinez; Esther Herrera-Luis; Maria Pino-Yanes; Gregory A Hawkins; Elizabeth J Ampleford; Susan J Kunselman; Corey Cox; Leonard B Bacharier; Michael D Cabana; Juan Carlos Cardet; Mario Castro; Loren C Denlinger; Celeste Eng; Anne M Fitzpatrick; Fernando Holguin; Donglei Hu; Daniel J Jackson; Nizar Jarjour; Monica Kraft; Jerry A Krishnan; Stephen C Lazarus; Robert F Lemanske; John J Lima; Njira Lugogo; Angel Mak; Wendy C Moore; Edward T Naureckas; Stephen P Peters; Jacqueline A Pongracic; Satria P Sajuthi; Max A Seibold; Lewis J Smith; Julian Solway; Christine A Sorkness; Sally Wenzel; Steven R White; Esteban G Burchard; Kathleen Barnes; Deborah A Meyers; Elliot Israel; Michael E Wechsler Journal: Lancet Child Adolesc Health Date: 2021-11-09
Authors: Anastasia Ivanova; Elliot Israel; Lisa M LaVange; Michael C Peters; Loren C Denlinger; Wendy C Moore; Leonard B Bacharier; M Alison Marquis; Nathan M Gotman; Michael R Kosorok; Chalmer Tomlinson; David T Mauger; Steve N Georas; Rosalind J Wright; Patricia Noel; Gary L Rosner; Praveen Akuthota; Dean Billheimer; Eugene R Bleecker; Juan Carlos Cardet; Mario Castro; Emily A DiMango; Serpil C Erzurum; John V Fahy; Merritt L Fajt; Benjamin M Gaston; Fernando Holguin; Sonia Jain; Nicholas J Kenyon; Jerry A Krishnan; Monica Kraft; Rajesh Kumar; Mark C Liu; Ngoc P Ly; James N Moy; Wanda Phipatanakul; Kristie Ross; Lewis J Smith; Stanley J Szefler; W Gerald Teague; Michael E Wechsler; Sally E Wenzel; Steven R White Journal: J Biopharm Stat Date: 2020-09-17 Impact factor: 1.051
Authors: Elliot Israel; Juan Carlos Cardet; Jennifer K Carroll; Anne L Fuhlbrigge; Wilson D Pace; Nancy E Maher; Lilin She; Frank W Rockhold; Maureen Fagan; Victoria E Forth; Paulina Arias Hernandez; Brian K Manning; Jacqueline Rodriguez-Louis; Joel B Shields; Tamera Coyne-Beasley; Barbara M Kaplan; Cynthia S Rand; Wilfredo Morales-Cosme; Michael E Wechsler; Juan P Wisnivesky; Mary White; Barbara P Yawn; M Diane McKee; Paula J Busse; David C Kaelber; Sylvette Nazario; Michelle L Hernandez; Andrea J Apter; Ku-Lang Chang; Victor Pinto-Plata; Paul M Stranges; Laura P Hurley; Jennifer Trevor; Thomas B Casale; Geoffrey Chupp; Isaretta L Riley; Kartik Shenoy; Magdalena Pasarica; Rafael A Calderon-Candelario; Hazel Tapp; Ahmet Baydur Journal: Contemp Clin Trials Date: 2020-12-11 Impact factor: 2.226
Authors: Anne M Fitzpatrick; Leonard B Bacharier; Daniel J Jackson; Stanley J Szefler; Avraham Beigelman; Michael Cabana; Ronina Covar; Theresa Guilbert; Fernando Holguin; Robert F Lemanske; Fernando D Martinez; Wayne Morgan; Wanda Phipatanakul; Jacqueline A Pongracic; Hengameh H Raissy; Robert S Zeiger; David T Mauger Journal: J Allergy Clin Immunol Pract Date: 2020-03-07
Authors: Jasmine I Caulfield; Allison M Ching; Erin M Cover; Avery August; Timothy Craig; Helen M Kamens; Sonia A Cavigelli Journal: Psychopharmacology (Berl) Date: 2020-10-04 Impact factor: 4.530